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Abstract
The concept of Vascular Dementia (VaD) has been recognized for over a century, but its definition
and diagnostic criteria remain unclear.
Conventional definitions identify the patients too late, miss subjects with cognitive impairment
short of dementia, and emphasize consequences rather than causes, the true bases for treatment
and prevention. We should throw out current diagnostic categories and describe cognitive
impairment clinically and according to commonly agreed instruments that document the
demographic data in a standardized manner and undertake a systematic effort to identify the
underlying aetiology in each case.
Increased effort should be targeted towards the concept of and criteria for Vascular Cognitive
Impairment and Post-Stroke Dementia as well as for genetic factors involved, especially as these
categories hold promise for early prevention and treatment.
Background
The concept of Vascular Dementia (VaD), has been recog-
nized for over a century, but its definition and diagnostic
criteria remain unclear and generate, much confusion and
debate althoung several clinical criteria have been used for
defining the VaD
The term of VaD substantially means "disease with a cog-
nitive impairment resulting from cerebrovascular disease
and ischemic or hemorrhagic brain injury".
Dementia represents only a portion of the burden of cog-
nitive dysfunction associated with cerebrovascular dis-
ease. In addition to patients who develop dementia, there
are those who develop cognitive impairment that does
not fulfill traditional criteria for dementia but that none-
theless has a significant impact on quality of life and abil-
ity to carry out activities of daily living. As a result, the
older term "vascular dementia" is being replaced with a
new one: "vascular cognitive impairment" (VCI). In addi-
tion, postmortem pathological studies indicate that 15%
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pathology, either alone or in combination with Alzheimer
disease (AD) pathology [1].
In fact, dementia criteria are typically modelled on Alzhe-
imer Disease (AD), wherein involvement of the mesial
temporal lobe results in dense episodic memory impair-
ment. [2,3]. Current research has led to the identification
of a cognitive syndrome signalling a high risk of further
cognitive decline, a group of patients similar to that of
mild cognitive impairment as a risk state for AD [4]. The
cognitive impairment attributable to cerebrovascular dis-
ease is a rapidly escalating public health problem. The het-
erogeneity of the population of patients with VaD
diagnosed using current criteria has raised the need for
updating the classification of subtypes
History
The concept of "dementia" originated early in the 16th
century., when for the first time Pratensis mentioned the
"Dementia stroke correlate". in the "De cerebri morbis -
1549" Subsequently Willis described the most important
causes of dementia including ageing and vascular disease
and the first accurate clinical observations of patients with
vascular dementia In the early 19th century Cooke
described "intellectual deficits among the sequelae of apo-
plexy" The history of vascular dementia during 19th and
20th centuries has been recently reviewed [5].
Binswanger and Alzheimer, began a series of clinico-
pathological correlation studies attempting to isolate
additional forms of dementia, describing four different
form of vascular dementia (arteriosclerotic brain degener-
ation, perivascular gliosis of the brain cortex, dementia
post-apoplexian and Binswanger's chronic progressive
subcortical encephalitis) [6-16]. Pierre Marie described in
1901 the "état lacunaire" associated with a constant intel-
lectual deficits. Dementia was separated from delirium
and other psychiatric diseases at the end of the 19th cen-
tury, but its etiology remained un cleared [17].
Alzheimer and Binswanger had correctly concluded that
"arteriosclerotic dementia" represented a large clinico-
pathological spectrum. However, "arteriosclerotic demen-
tia" incorrectly became synonymous with senile demen-
tia, and it was widely held that cortical atrophy in the
elderly resulted from progressive decrease in cerebral per-
fusion leading to hypoxic neuronal death.
Little further progress was made for the next 70 years
because of a combination of factors (Freud's work,
Kraepelin's classification, syphilis as a common and
obscuring cause of dementia). New suggestions and
observations were made, but they did not thrive against
this background. In 1946 a clear description of a multi-
infarct dementia was given, recognizing the possible role
of silent infarcts and explicating that the chronic ischemia
wasn't he cause of vascular dementia, but the true mecha-
nism was the infarction. This process later termed "multi-
infarct dementia" [18]
Today, the importance of vascular lesions in Alzheimer's
disease is being increasingly recognized: various data
shows that more than 30% of AD exhibit cerebrovascular
pathology [5].
A recent review define the AD as a vascular disorder:
"...since the value of scientific evidence generally revolves
around probability and chance, it is concluded that the
data presented here pose a powerful argument in support
of the proposal that AD should be classified as a vascular
disorder. According to elementary statistics, the probabil-
ity or chance that all these findings are due to an indirect
pathological effect or to coincidental circumstances
related to the disease process of AD seems highly unlikely.
The collective data presented in this review strongly sup-
port the concept that sporadic AD is a vascular disorder."
[19].
Discussion
Vascular dementia (VAD) and vascular cognitive 
impairment (VCI): clinical criteria
Cardinal elements implemented in the clinical criteria for
VaD are the definition of the cognitive syndrome of
dementia and the objective documentation of vascular
lesions capable of causing dementia [20-24]. All the cur-
rently clinical criteria, are derived from expert opinion
based on prevailing knowledge and pathogenetic hypoth-
esis of dementia's causes [25].
The current clinical criteria for VaD recognize the multi-
plicity of lesions, but none of these clinical criteria pro-
vide guidelines for subtype of VaD [26]. Only the NINDS-
AIREN criteria mention the following subtype: cortical
vascular dementia, Binswanger's disease and thalamic
dementia [27]. Also the brain imaging requirements are
not included, or are not complete, in all current clinical
criteria.
The systematic heterogeneity of the population of patients
with VaD diagnosed by using current criteria has raised
the need for updating the classification of subtypes. The
main subtype of VaD include: multi-infarct dementia or
predominantly cortical VaD, strategic infarct dementia
and small vessel dementia or subcortical VaD even if only
subcortical VaD is probably a more homogenous group
[28-31]
The new criteria are based on homogeneity (in aetiologies,
brain imaging and clinical syndrome), on predictabilityPage 2 of 9
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natural history, outcomes and treatment responses), on
reproducibility (intra- and inter-rater reliability). Further-
more, they must be validated by prospective clinical path-
ological correlation [25,32].
The cornerstone of all criteria of dementia is memory
impairment; this criterion works very well for AD, in
which the mesial temporal lobes are affected early and
prominently with consequent early memory loss, but
strokes affecting cognition occur most commonly in the
frontobasal systems that subserves judgement, planning
and emotion, features seldom tested in cognitive screens.
At present, there is no generally accepted test battery for
identifying or classifying patients with VCI. However,
there are some basic principles that can be followed in
developing such a battery. One of these is that large vessel
cortical strokes and subcortical small vessel disease, tend
to produce different kinds of deficits. The former typically
present with region-specific syndromes such as aphasia,
apraxia, and amnesia. The latter present with more subtle
and temporally progressive deficits, often described as
"executive" in nature. [4,33-37]. These include deficits in
speed and so-called "strategic" processing (ie, attention,
planning, and monitoring) in tasks such as memory tasks.
Patients may perform normally on simple tasks but reveal
deficits as tasks increase in complexity. It appears that the
majority of VCI patients fall into the class with subcortical
small vessel disease. [21,38]. Thus, it seems reasonable
that neuropsychological testing for VCI would include
tasks testing executive function. In addition, such tests
may help to differentiate patients in which either vascular
or AD pathologies predominate [1]
The extent of ischaemic disease on neuroimaging, that is
both sufficient and necessary to cause cognitive impair-
ment, Leukoaraiosis and atrophy as well as the issue of
location [39]. To summarize the literature data, it's clear
that there are insufficient data to propose firm cut-offs for
the extent of Leukoaraiosis or for extent of infarction.
Anyway, enough scientific rationale already exists for
undertaking systematic clinical trials in the prevention of
cognitive impairment through the control of vascular risk
factors and the use of statins, anti-inflammatory agents,
ACE inhibitors, vitamins E and B12 [40].
Epidemiology
Epidemiologic studies of VaD have been hampered by the
"lack of clear and universal diagnostic criteria, by the use
of different strategies in detecting dementia cases of vascu-
lar origin, by the difficulties of developing an effective
case-finding strategy, and by the complexity of using
imaging or laboratory tests in large scale epidemiologic
surveys" [41]. Despite these difficulties, the broad con-
tours of VaD epidemiology are emerging slowly [42-44].
The data from current studies cannot be compared and
reconciled easily. Diagnostic criteria for VaD have been a
long standing source of disagreement and are perhaps the
greatest barrier to reaching consensus on the epidemiol-
ogy of this disease [42,43,45]. A first problem is the clas-
sification of patients with the so-called "mixed" dementia,
in whom the aetiology appears to include both cerebrov-
ascular and primary degenerative features. A second prob-
lem is the disagreement about criteria and evaluation of
tools. A number of new sets of criteria have been intro-
duced in the 1990s, including the ICD-10, the Chui et al.,
the Roman et al., and the DSM-IV criteria [46,47]. An
additional problem with epidemiologic studies is the
need to transfer published criteria into clinical instru-
ments or procedures that can be implemented on a large
scale. Brief scales to separate VaD from AD have been
developed beginning with the Hachinski Ischemic Score
(HIS) introduced in 1975. A number of modifications or
transformations of this original scale have been proposed
in the past 20 years [48]. Some of these scales require
imaging tests, whereas others are purely clinical. A third
problem is the use of imaging findings in the definition of
VaD: in the incidence study of dementia in Rochester, the
age-specific incidence rate of VaD by using more restric-
tive DSM-IV criteria (clinical stroke required) and less
restrictive criteria (certain vascular imaging lesion suffi-
cient) diverge beyond 70 years of age, and are more than
doubled with the restrictive criteria beyond 85 years of age
[49]. A fourth problem is to define the range of severity of
VaD to be detected in the study: severity may vary from a
mild cognitive impairment to terminal stages of deteriora-
tion.
If the prevalence of VaD is greater among women than
men of a certain age, it remains uncertain whether women
have a higher incidence of VaD or whether the incidence
is equal to men, but survival after onset of VaD is better in
women [41].
Today new prevalence studies are available) and the
breadth of variation for VaD prevalence is now even
wider. It remains unclear whether the differences between
different countries reflect disagreement over diagnostic
criteria for VaD or other methodological differences. For
studies investigating the incidence of VaD in different
countries the data are similarly disparate [50,34].
The data available to answer the question if the prevalence
or the incidence of VaD is increasing or decreasing over
time are very few. Because the data from current studies
cannot be easy reconciled, it remains very difficult to draw
conclusions about the epidemiology of VaD. Our progressPage 3 of 9
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of diagnostic criteria sensitive and specific, easy to apply
in the field setting and internationally accepted. It
appears, however, that the prevalence of VaD tends to be
higher in men than in women, and that it increases with
age; moreover there seems to have been a decline in both
prevalence and incidence of VaD between the 1950s and
1970s [41]. The prevalence of VaD ranged typically
between 3% and 6%; but the variation described ranged
between 0% to 20%. There are relatively few data regard-
ing incidence in the general population. The incidence of
cognitive impairment sufficient to adversely affect out-
come but not meeting current criteria for vascular demen-
tia is as high as 35.2% compared to 3.8% with a similar
degree of impairment in stroke-free controls [18,35,42].
Pathophysiology
Epidemiological studies have explored widely the poten-
tial risk factors or protective factors for different dement-
ing disorders [36,51]. Many studies have focused on AD
and more recently, on all types of dementia as a syn-
drome. Aetiological studies about VaD have been ham-
pered by methodological issues and - the search for risk
factors of VaD may potentially be more amenable to pre-
vention than AD [52].
Some common determinants between AD and VaD are:
- risk factors involved in cerebrovascular disease (age, sex,
some atherogenic disorders or vascular risk factors,
genetic factors and inflammation). Other potential risk
factors like occupational exposure to pesticide, psycholog-
ical stress or life events, dietary fat intake, family history of
stroke, etc.);
- potential protective factors (high educational attain-
ment, eating fish or shellfish, physical exercise, use of sup-
plementary antioxidants like Vitamins E and C, use of
Vitamin B12, Mediterranean diet, etc.) [36,50,53].
Vascular cognitive impairment is not a regular pathoge-
netic entity. Multiple small thromboembolic strokes or
strokes in strategic locations such as the thalamus, frontal
lobe or temporal lobes may cause cognitive impairment
and frequently occur without classical stroke-like symp-
toms. Nonetheless, in VaD, the majority of patients
instead present widespread microangiopathy-related cere-
bral damage, which is often clinically silent or is accompa-
nied by unspecific neurological signs.
Several mechanisms may explain why patients affected by
stroke are prone to develop dementia [20,37,54,55]:
- post-stroke dementia may be the direct consequence of
vascular lesions in the brain
- post-stroke dementia could be the result of pre-existing
neuropathological effects AD's related
- recurrent stroke that is cause by vessel damages and by
white matter lesions that may lead to cognitive decline
and contribute to post-stroke dementia;
One of the mechanism involved in ischemic VaD is under
the control of large vessels disease (atherosclerosis, and
other arteriopathies), however, impaired cerebral flow in
the absence of infarct as consequence of arterial stenosis
has been documented, although its clinical consequences
remain to be fully investigated. It is also unclear whether
and to what degree large vessel disease contributes to the
white matter pathology and lacunes associated with the
subcortical type of VaD. Statistical association suggests it
may have additive effects to small vessel pathology.
[56,57]
Moreover, the alterations of small vessels play a role in
causing damage to the cerebral tissue and are potentially
responsible for the subsequent development of cognitive
alterations. Small vessel lesions are considered related to
the deep lacunar infarcts and white matter changes typi-
cally observed in subcortical forms of vascular cognitive
impairment.
The most common types of diseases affecting cerebral
microvessels are: arteriosclerosis, lipohyalinosis, cerebral
amyloid angiopathy, basal ganglia calcification, CADASIL
(Cerebral Autosomal Dominant Arteriopathy with Sub-
cortical Infarcts and Leucoencephalopathy), other
uncommon intracerebral vasculopathies.
The small vessel alterations could also lead to damage
affecting the blood-brain barrier and chronic leakage of
fluid and macromolecules in the white matter, even if the
neuroimaging methods do not detect diffuse alterations
of the blood-brain barrier in vivo [58].
Another mechanism influencing small vessel alterations
could be incomplete ischemia and selective tissue necrosis
(i.e. incomplete infarction) causing a selective neuronal
necrosis with sparing of glial cells and microvessels [59-
62].
Recently, it has been suggested a new variety of lacunar
infarction, (type Ib), characterized by small areas of
perivascular rarefaction and selective neuronal loss, fol-
lowed in the more advanced stages by a varying amounts
of depleted neurons and oligodendrocytes, astroglial
response and minor central cavitation. Furthermore,
embolic occlusion of small penetrating artery followed by
spontaneous lyses of the thrombus could be responsible
for these lacunes [63-65].Page 4 of 9
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was introduced to describe morphological abnormalities
of the white matter on imaging [66].
The pathogenesis of white matter changes (WMC) is not
well established and a number of possible mechanisms
have been hypothesized, all mechanisms are reconducible
to a form of cerebrovascular disease. It has been proposed
that the diffuse changes of the white matter should be
considered a form of incomplete infarction. [67-76]
The understanding of the pathobiology of AD and VaD
recived an impulse by the discovery of genes that produce
monogenic forms of the illness or contribute to polygenic
forms; in particular, the identification of genes contribut-
ing to VCI would no doubt provide insight into the cellu-
lar and molecular basis of VCI.
Genetic factors play an important role in the aetiology of
VaD, in particular, it's seems to be more important in
large-vessel stroke and small vessel stroke than in cryp-
togenic stroke, and there is no epidemiological evidence
for a genetic component in cardioembolic stroke.
The genes underlying VaD must be of 2 nonmutually
exclusive classes: (1) genes that predispose individuals to
cerebrovascular disease, and (2) genes that determine tis-
sue responses to cerebrovascular disease (eg, genes con-
veying ischemic tolerance or susceptibility, or the ability
to recover from ischemic insult). With regard to the first
class of genes, some progress has been made in the past
few years in identifying genes that confer susceptibility to
hypertension and stroke [77]. In addition, several mono-
genic forms of cerebrovascular disease have been identi-
fied. The two best studied of these are cerebral autosomal
dominant arteriopathy with subcortical infarcts and leu-
coencephalopathy (CADASIL: a subcortical small vessel
disease accompanied by lacunar strokes, migraine, and
dementia) and hereditary cerebral hemorrhage with amy-
loidosis-Dutch type (HCHWA-D) [1].
The CADASIL condition is a heritable small-vessel disease
caused by mutations in NOTCH3 gene which is normally
expressed in vascular smooth muscle cells and pericytes
(including those of the cerebral vasculature) and that
encodes a cell-surface receptor, which has a role in arterial
development and is expressed on vascular smooth-muscle
cells. appears to be involved in directing smooth muscle
cell proliferation and differentiation. The NOTCH3 recep-
tor is a heterodimer composed of a large extracellular frag-
ment and a smaller transmembrane intracellular
fragment. About 95% of patients have missense muta-
tions that cluster in exons 3- and consist in change of
cysteine residues amount, but the pathogenic meccanism
is still unknown [78,79].
Whit regard to HCHWA-D (a syndrome of primarily hem-
orrhagic strokes and dementia), it is caused by a mutation
in the gene for amyloid precursor protein (APP) that
causes abnormal deposition of amyloid in the walls of
leptomeningeal arteries and cortical arterioles (a mpatho-
logical condition known as cerebral amyloid angiopathy
[CAA]). Mouse models have been developed for CADASIL
and HCHWA-D and have contributed critical insights into
the cell biology of the pathogenic processes underlying
them. [80]
In contrast, little attention has been paid to the second
class of genes: those that render the brain more or less sus-
ceptible to injury in response to cerebrovascular disease.
Evidence for the existence of such response genes is that
patients with apparently similar loads of vascular pathol-
ogy (with regard to lesion type, number, and location)
may range from no cognitive impairment to severely cog-
nitively impaired. The association studies using the candi-
date gene approach, has identified a number of genetic
variants possibly involved in risk factor development and,
on the other hand, suggests that the risk of stroke has a
substantial genetic component. Nonetheless, the genes
underlying this risk in the general population remain
undetermined. Genetic factors can act at several levels.
They can contribute to conventional risk factors such as
hypertension, diabetes, or homocysteine concentrations,
which have a known genetic components. They might fur-
ther interact with environmental factors or contribute
directly to an intermediate phenotype [78,81]
It is also possible that some genetic factors contribute, by
interaction with conventional risk factors, to the develop-
ment of subcortical injury of vascular origin in non famil-
iar cases.
Most single-gene disorders are associated with specific
stroke subtypes, especially in young stroke patients with-
out known risk factors. Table 1; ref. [79,82-87].
In this group of diseases we take in consideration only
Fabry's disease for its special association with stroke. The
Fabry's disease is an X-linked systemic disorder caused by
deficiency of the lysosomal enzyme α-galactosidase A,
that results in progressive accumulation of glycosphingol-
ipids in the myocardium, renal epithelium, skin, eye, and
vasculature. The symptoms are acroparesthesia, angiok-
eratoma, hypoidrosis, which start during the childhood or
adolescence and are present in the majority of the affected
individuals and many young patients are affect by cryp-
togenetic stroke. The disease occurs either in large-artery
either in small-vessel disease, with a preference for poste-
rior circulation. Small-vessel disease in Fabry's disease is
associated with white-matter changes and evidence sug-
gests that the extent of such lesions is influenced by genePage 5 of 9
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synthase, factor V, and protein Z [78,82]. These findings
are suggestive but need further confirmation (Duro's data
not published).
The genetic contribution to common multifactorial stroke
seems to be polygenic: there are many alleles with small
effect, due to their wide distribution, however, on a pop-
ulation basis the impact on stroke is large. Several genes
and polymorphisms were selected for a significant associ-
ation with ischaemic stroke: in particular polymorphisms
in the genes encoding MTHFR (enzyme in homocysteine
metabolism), ACE (enzyme in renin-angiotensin-aldos-
terone system), Factor V Leiden, prothrombin and PAI 1
(Haemostatic system) [78]
Recently, studies for the analyses of ischemic stroke
assessed two unsuspected common SNPs on chromosome
12p13 (rs11833579 and rs12425791), consistently asso-
ciated with total ischemic, and atherothrombotic stroke in
caucasic population although there is association with
ischemic and atherothrombotic strokes (as compared
with total stroke), but no association with non ischemic
stroke. The SNPs are on the gene NINJ2 that encodes an
adhesion molecule expressed in glia cells and shows
increased expression after nerve injury Some mutations
are associated with a slightly more aggressive phenotype.
[81].
One class of genes that must influence tissue responses to
cerebrovascular disease are the AD genes. There is an addi-
tive or synergistic interaction between AD and cerebrovas-
cular pathologies, such that individuals with both of these
pathologies show greater cognitive impairment than
those exhibiting either pathology alone. In addition, at
least three sets of genes in the AD pathway, the preseni-
lins, APP, and apolipoprotein E (apoE), are known to
interact with the VCI disease pathway.
The presenilins, mutations of which cause AD, have been
shown to interact directly with Notch proteins, including
Notch 3 (mutations of which cause CADASIL).
Mutations in the APP gene can lead either to AD or to
hemorrhagic stroke and dementia (as in HCHWA-D)
depending on the site of the mutation and the subsequent
cellular site of amyloid accumulation.
Variants of the apoE gene appear to affect not only suscep-
tibility to cerebrovascular disease but also recuperative
responses to it (see below). Thus, there appear to be links
in the biochemical pathways underlying VCI and AD
pathologies, which could be responsible for the observed
interactive effects of these pathologies on cognitive func-
tion.
Genes that influence brain responses to cerebrovascular
disease do not appear to be limited to those within AD
pathway. First, it has been shown that VCI can occur in the
complete absence of AD pathology in sporadic VCI and in
hereditary forms. In addition, the cognitive sequelae of
pathogenic processes associated with VCI are different
from those seen in "pure" AD, in that executive function
appears more strongly affected in VCI than is memory.
Consistent with these observations, different brain
regions seem differentially affected in VCI and AD, with
prefrontal circuits being more affected in VCI and the hip-
pocampus in AD.
An important aspect of VaD's (AD's particular) patho-
physiology, is the role of inflammation: the incidence is
influenced by the gene polymorphisms of the inflamma-
tory mediators. Among the most widely investigated
genes are those involved in inflammation (interleukin 1,
interleukin 6, TNFα, toll-like receptor 4, P-selectin and E-
selectin, C-reactive protein), lipid metabolism (apolipo-
protein E, paraoxonase, epoxide hydrolase), nitric oxide
Table 1: Single-gene disorders associated with ischaemic stroke (for reference see the text)
Gene Disease Mode of 
inheritance
Stroke mechanism
GAL Fabry's disease X-linked Large-artery disease and small-vessel disease
NOTCH3 CADASIL AD Small-vassel disease
HBB Sickle-cell disease AR Large-artery disease, small-vessel disease, haemodynamic insufficiency
CBS and others Homocystinuria AR Large-artery disease, cardioembolism, small-vessel disease, arterial dissection
mtDNA MELAS Maternal Complex (microvascular and neuronal factors)
FBN1 Marfan syndrome AD Cardioembolism and arterial dissection
COL3A1 Ehlers-Danlos syndrome type IV AD Arterial dissection
ABCC6 Pseudoxanthoma elasticum AR Large-artery disease and small-vessel disease
AD = autosomal dominant. AR = autosomal recessive. HBB = haemoglobin beta. CADASIL = cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leucoencephalopathy. MELAS = mitochondrial myopathy, encephalopathy, lactacidosis, and stroke. mtDNA = mitochondrial 
DNA.
For references, see textPage 6 of 9
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ases) [88,89].
Infact, in recent years, an increasing set of evidence has
stress the role of inflammation in the brain, particularly in
the microglia-rich amyloid deposits, where the microglias
tend to release a wide variety of proinflammatory media-
tors including cytokines (IL 1β, IL 6, TNF α, acute phase
proteins) complement components, various free radicals
and nitric oxide (NO), all of which potentially contribute
to further neuronal dysfunction and eventually result in
cellular death. In addition, apolipoprotein E (ApoE) is
strongly associated with AD in terms of cognitive decline
and disease onset: ApoE, especially the ε4 allele, has been
observed promoting an inflammatory reaction[14]. The
AD's pathomechanism is related to the accumulation of
toxic amyloid-β (Aβ), which precipitate along the vessel
walls and in brain parenchymal plaques, as well as the for-
mation of neurofibrillary tangles (NFTs); the develop-
ment of cognitive impairment in VaD may be related to a
number of different pathological processes including
multiple infarctions resulting from occlusion of major
brain vessels or their branches and lypohyalinosis. The
latter is a degeneration of small arterial vessel walls sup-
plying the subcortical white matter, thalamus, and basal
ganglia, or cerebral amyloid angiopathy (CAA is the accu-
mulation of amyloid protein in the walls of cerebral
blood vessels): less commonly, vascular dementia is
related to deposition of Aβ in brain vessels. CAA can be
either sporadic or familial. The progressive cognitive
impairment in CAA results from multiple brain hemor-
rhages and/or ischemia related to narrowing of vessel
lumen [88,90]
Conclusion
We should throw out current diagnostic categories and
describe cognitive impairment clinically and according to
commonly agreed instruments that document the demo-
graphic data in a standardized manner and undertake a
systematic effort to identify the underlying aetiology in
each case (imaging and DNA should be obtained when-
ever possible.
However, further empirical research and international
debate is needed to define the syndrome and stages of vas-
cular subcortical cognitive impairment, validate the brain
imaging criteria for subcortical Vascular Dementia by clin-
ical-pathological correlation, as well as the natural history
and outcomes of the syndrome.
Increased effort should be targeted towards the concept of
and criteria for Vascular Cognitive Impairment and Post-
Stroke Dementia as well as for genetic factors involved,
especially as these categories hold promise for early pre-
vention and treatment.
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